Articles tagged with Pancreatic Cancer
Research found that individuals with gum disease have an increased risk of various cancers, including lung, kidney, and pancreatic cancers. Gum disease was associated with a 14% higher overall cancer risk compared to those without gum disease.
Researchers at OHSU have developed new antibodies that can recognize pancreatic cancer and gastrointestinal cancers. These antibodies show promise in early detection and treatment of pancreatic cancer, which is the fourth-leading cause of cancer death in the US.
GAL-3 stimulates pancreatic stellate cell activation, which promotes the proliferation and invasion of pancreatic cancer cells. This interaction provides a new therapeutic target for controlling pancreatic cancer.
Researchers found that endoscopic ultrasound improves patient outcomes after diagnosis with pancreatic cancer. Heavy smoking and drinking are linked to an earlier onset of the disease, with beer being the strongest contributor.
Researchers found that thymoquinone blocked pancreatic cancer cell growth and killed cells by enhancing programmed cell death, with 80% of cancer cells killed. Thymoquinone also triggered epigenetic changes, including acetylation of histones, which could lead to new cancer treatments.
The University of Pittsburgh Cancer Institute has established a groundbreaking BRCA cancer research program focusing on genetic mutations that significantly increase breast, prostate, ovarian, and pancreatic cancer risks. The program aims to identify innovative ways to reduce the risk for high-risk patients.
Researchers found that calorie restriction hinders development of pancreatic cancer by reducing levels of IGF-1 and inflammatory signaling proteins. Only 7.5% of mice on the calorie-restricted diet developed lesions, compared to 45% and 57.5% in overweight and obese groups.
Two new therapies have shown promising results in treating basal cell carcinoma and pancreatic cancer. A novel molecule, GDC-0449, has been found to shrink tumors with limited side effects, while a combination of two drugs has shown significant clinical benefit in over 80% of pancreatic cancer patients.
Researchers present data on the preventive effects of celecoxib and atorvastatin in colorectal, prostate and breast cancer. The study found that patients taking celecoxib had a significant reduction in adenomas, precursor to colon cancer, with low cardiovascular risk. A combination of atorvastatin and celecoxib also inhibited the growt...
Researchers at Thomas Jefferson University have found that common blood pressure medications can inhibit pancreatic cancer cell growth and cause cell death. The study suggests that these drugs may be part of a novel strategy to control the growth and spread of cancer.
Researchers found that nicotine increases osteopontin production, promoting cancer cell survival and spread. Elevated osteopontin levels have been detected in pancreatic cancer patients, suggesting a potential role in the cigarette smoking-pancreatic cancer connection.
A study found that adding gemcitabine to chemoradiation improved survival rates for pancreatic cancer patients who had surgery, but the benefit was not statistically significant. The treatment reduced local relapse and systemic metastasis in patients.
Researchers have discovered that heart hormones can eliminate human pancreatic and breast cancers in mice, reducing tumors by up to 97%. The treatment has shown no side effects and has the potential to make cancer a chronic condition.
Researchers at Baylor College of Medicine discovered that mesothelin, a protein found on tumor cells' surface, promotes pancreatic cancer growth. A new vaccine targeting mesothelin, made from virus-like particles, has shown promise in slowing tumor growth and increasing survival time in mice.
A new study by Saint Louis University researchers found a striking correlation between patient prognosis and tumor size at diagnosis. Patients with tumors under 20mm had the highest median survival rates, but only accounted for 18% of cases.
Scientists discovered that metastatic pancreatic cancer cells produce enough of the protein IDO to evade detection by the immune system, allowing them to spread in the body. This finding may lead to new ways to detect pancreatic cancer spreading to lymph nodes and enhance tumor immune therapy strategies.
Researchers found that ZIP4, a zinc transporter, is overexpressed in pancreatic cancer tissue and promotes tumor growth. The study provides a potential diagnostic marker and candidate for cancer vaccine development.
Researchers present emerging therapies targeting cancer cells, including a small molecule inhibitor of protein kinase D and an oncolytic herpes virus that selectively targets cancer cells without damaging nerves. These treatments offer promising methods for controlling disease and improving patient outcomes.
A study found that diabetes increases levels of CA 19-9, a tumor marker for pancreatic cancer. Elevated CA 19-9 levels in diabetics may indicate chronic pancreatitis rather than pancreatic cancer.
Researchers at Jefferson University have discovered a tumor-blocking protein, pp32, that may be missing in aggressive forms of pancreatic cancer. The absent protein could eventually serve as a biomarker for the disease and a potential therapeutic target.
Eating flavonol-rich foods like apples may help reduce pancreatic cancer risk, with quercetin identified as a key compound. Smokers who consumed more flavonols had a significantly greater risk reduction.
A new study found that gemcitabine chemotherapy after surgery doubles disease-free survival from 4.9 to 11.4 months in patients with operable pancreatic cancer, improving outcomes by 41 percent
Researchers identified a distinct subpopulation of cancer stem cells responsible for metastasis in human pancreatic cancer. The study found that CSCs expressing CD133 and CXCR4 play a critical role in tumor metastasis, and inhibiting these cells or transplanting non-metastatic cells can abolish metastatic tumor development.
Researchers at the University of Georgia are working on a new approach to detect pancreatic cancer using subtle changes in proteins and sugars. They believe that these biomarkers can be found in pancreatic fluid and blood, which could lead to earlier detection and improved treatment outcomes.
Researchers found a blood protein, IGFBP-1, linked to obesity and exercise aversion may indicate increased pancreatic cancer risk. The study suggests lifestyle factors modifiable for improved prognosis.
Researchers found that people with low IGFBP-1 levels were twice as likely to develop pancreatic cancer as those with higher levels. This protein's role in modulating insulin and IGF hormones may hold clues to the disease's development, potentially aiding in risk prediction.
Research suggests women with a history of gestational diabetes are at higher risk of developing pancreatic cancer. A study of over 37,000 mothers who gave birth in Jerusalem between 1964 and 1976 found five cases of pancreatic cancer among those with gestational diabetes.
A new optical technology has been developed to detect early signs of pancreatic cancer, allowing for earlier diagnosis and potentially improving treatment outcomes. The technique uses a minimally invasive procedure that can identify cancerous tissue with high accuracy, even in patients with chronic pancreatitis or family history.
Researchers developed a novel technology using light to probe tissue architecture, enabling subtle changes in tissue to be detected. The technique produced an optic fingerprint from altered tissue, distinguishing patients with cancer at an accuracy approaching 100 percent.
Researchers found that nimesulide, a COX-2 inhibitor, delayed the development of precancerous pancreatic lesions in mice by 90%, potentially offering a new approach to preventing pancreatic cancer in high-risk populations. The study suggests that inhibiting COX-2 may help slow or prevent the progression of pancreatic cancer.
A Northwestern University-developed optical technology has been found to be effective in the early detection of colon cancer, now appearing promising for detecting pancreatic cancer. The technique can detect abnormal changes in cells lining the duodenum without touching or imaging the pancreas.
Researchers have identified IL6 as a protein that stimulates tumor growth when activated by Ras, leading to increased blood vessel formation. Suppressing IL6 activity has shown promising results in fighting tumor formation in preclinical models.
Researchers at the University of Texas M. D. Anderson Cancer Center have developed a gene therapy that selectively targets and eliminates pancreatic cancer cells, inhibiting metastasis and prolonging survival with minimal toxicity. The therapy, called VISA-BikDD, has shown significant promise in preclinical trials, with treated mice su...
A study led by University of Cincinnati scientists has found that the RON receptor is overexpressed in pancreatic cancer cells, suggesting a link between the receptor and disease development. The researchers believe blocking the receptor's signaling pathways could lead to new therapies for this deadly disease.
Scientists create a new adenovirus that selectively targets cancer cells with high dNTP concentrations, potentially delivering genetic materials to destroy malignant cells. The approach has shown promise in testing mice and human pancreatic cancer cells.
Researchers found that consuming high amounts of vitamin B6, B12, and folate from food reduced the risk of pancreatic cancer by 59%, 73%, and 81% respectively. In contrast, multivitamin use was associated with a higher risk of developing the disease.
Recent research evaluates the progress made to date in diagnosing and treating pancreatic cancer, highlighting promising new applications of technology that will improve survival rates. The studies also identify key predictors of malignancy, including age, gender, symptoms, and radiographic features.
A recent study evaluated the incidence of malignancy in small pancreatic tumors and identified predictors such as age, gender, symptoms, and radiographic features. The findings suggest that very small tumors with no other symptoms or radiographic indicators have a low risk of malignancy.
A large cohort study found that using Swedish moist snuff (snus) increases the risk of developing pancreatic cancer by twice the rate of non-users. The study, conducted on almost 300,000 male construction workers, suggests that while the risks are small, snus use can still be a concern for overall health.
A recent study published in The Lancet found that Swedish snus is associated with a higher risk of pancreatic cancer, despite being less harmful than smoking. However, switching from cigarettes to snus can potentially lead to significant health benefits for smokers.
Researchers at Ohio State University Comprehensive Cancer Center have discovered a way to distinguish pancreatic cancer from non-cancerous tissue using microRNA molecules. The study found that specific miRNAs can predict patient survival rates, with correlations seen in just a few miRNAs that were not previously associated with the dis...
A new study identified genetic markers that can distinguish between chronic pancreatitis and pancreatic cancer, as well as predict patient outcomes. The discovery represents a significant advancement in cancer diagnostics and may lead to improved therapy options.
Scientists discovered a global expression pattern of microRNAs that can differentiate between pancreatic cancer and normal pancreas with high accuracy. The study found that specific miRNA expressions were associated with long-term survival and poor prognosis, offering potential for personalized treatment.
A new stent has been shown to relieve GI upper cancer distress by incorporating an anti-reflux valve, which reduces backflow of intestinal contents into the bile duct. The study found that patients with the Dua stent had a longer median of 145 days without complications compared to those with standard stents.
A new pancreatic cancer vaccine has successfully stalled disease progression in a handful of patients three years post-vaccination, offering new insights into how the vaccine could be made more effective. The study found that the vaccine triggered an active immune response and slowed down cancer growth in four patients.
New cancer vaccine studies are making progress in developing vaccines that can attack cancerous cells by stimulating the immune system. Researchers have found that a human papillomavirus vaccine continues to protect against HPV types 16 and 18, as well as other related viruses, with significant cross-protection.
A study from the University of Pittsburgh Cancer Institute found that triphala extracts can prevent or slow pancreatic cancer tumor growth in mice by inducing apoptosis. The herb was shown to activate tumor-suppressor genes, supporting the generation of proteins that promote cell death in cancer cells.
A new computer software tool, PancPRO, helps genetic counselors and physicians predict the chance of carrying a gene for hereditary pancreas cancer and the lifetime risk of developing the disease. The model, developed by Johns Hopkins Kimmel Cancer Center researchers, calculates a percentage score of probability that a person carries a...
Researchers have discovered a biological mechanism whereby two compounds in broccoli and soy reduce the invasive and metastatic potential of breast and ovarian cancer cells. Studies also suggest that a diet high in flavonols may help reduce pancreatic cancer risk, especially in smokers.
A protein called tissue transglutaminase (TG2) protects human pancreatic cancer cells from autophagy, a form of programmed cell death, researchers found. Inhibiting TG2 led to a drastic reduction in its expression and telltale signs of autophagy in the cancer cells.
A study published in Cancer Cell reveals that a specific sequence of genetic mutations determines the behavior of cystic pancreatic cancer, which has a 50% long-term survival rate. The research found that cells with this mutation are resistant to TGFb's tumor-promoting properties, contributing to their improved survival.
Researchers at Michigan State University found that polycyclic aromatic hydrocarbons (PAHs) produced by burning tobacco interfere with cell communication, promoting pancreatic cancer. PAHs do not initiate cancer but contribute to its promotion.
Researchers identified a small number of cells in pancreatic cancer capable of fueling tumor growth, which are thought to be the cancer stem cells. These cells can replicate and produce new tumors, making them a crucial target for therapy.
Researchers identified human pancreatic cancer stem cells, which can produce tumors in half of mice tested. These stem cells are highly tumorigenic and resistant to traditional therapy, making them a promising target for new treatments.
Researchers at Mayo Clinic Cancer Center found that giving patients both radiation and chemotherapy after completely removing invasive pancreatic cancer significantly improves patient survival rates. More than half of the 454 patients who received adjuvant therapy survived two years, with a five-year survival rate of 28%.
A study found that chemotherapy with gemcitabine significantly delayed cancer recurrence in patients following pancreatic cancer surgery. The estimated median disease-free survival was 13.4 months for the gemcitabine group compared to 6.9 months for those without chemotherapy.
A new study by Harvard researchers has linked periodontal disease to an increased risk of pancreatic cancer. Men with periodontal disease had a 63% higher risk of developing the disease compared to those without it, after adjusting for other factors.
A new study found that calcium supplements can reduce the risk of colorectal adenoma recurrence by up to 5 years after stopping supplementation. In contrast, antioxidant supplements did not show a significant effect on gastric cancer risk.
Researchers have identified a unique pattern of microRNAs in pancreatic tumor tissue, suggesting a new way to diagnose and treat the disease. The findings may lead to more effective early detection and treatment of pancreatic cancer.
Researchers found that 201 patients (23%) lived five years after surgery, with at least half being 65 years old or older. Of those survivors, 65% lived another five years, nearly matching the general population's survival rate.